Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single center, phase II trial to evaluate the safety and efficacy of
postponing or omitting re-irradiation after first-line systemic therapy with tislelizumab and
chemotherapy in patients with unresectable recurrent loco-regionally advanced nasopharyngeal
carcinoma.